REG - Immupharma PLC - Grant of Share Options

ImmuPharmaAnnouncement

19/03/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240319:nRSS3189Ha&default-theme=true

RNS Number : 3189H  Immupharma PLC  19 March 2024

 
19 March 2024

ImmuPharma PLC

("ImmuPharma" or the "Company")

 

  Grant of Share Options

 

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development
company, announces the grant of share options as follows.

 

The Remuneration Committee (comprising the Non-Executive Directors) has
determined that the following unapproved Share Options have been awarded to
the Executive Directors with vesting  conditions which reflect the corporate
objective of restoring and enhancing shareholder value as follows:

 

Tim McCarthy                    8,000,000 share options
(exercise price £0.02)

Tim Franklin                       6,500,000 share options
(exercise price £0.02)

Sebastien Goudreau         5,000,000 share options (exercise price £0.02)

 

In addition, 5,500,000 unapproved Share Options have been awarded to other
employees/contractors with the same performance conditions.

 

Share Option Period: All Share Options are valid for 10 years from the date of
issue.

 

Time and Performance Conditions:

 

All Share Options will vest at the latter of:

 

·    When the Company has completed a new commercial deal of significant
value; and

·    3 years from the date of issue

The Remuneration Committee will determine when these conditions have been met.

 

ENDS

 For further information please contact:

ImmuPharma PLC (www.immupharma.com (http://www.immupharma.com) )  +44 (0) 207 206 2650

 Tim McCarthy, Chief Executive Officer

 Lisa Baderoon, Head of Investor Relations                         + 44 (0) 7721 413496

 SPARK Advisory Partners Limited (NOMAD)                           +44 (0) 203 368 3550 (about%3Ablank)

 Neil Baldwin

 Stanford Capital Partners (Joint Broker)                          +44 (0) 203 650 3650

 Patrick Claridge,  Bob Pountney

 SI Capital (Joint Broker)                                         +44 (0) 1483 413500

 Nick Emerson

Notes to Editors

 

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that
discovers and develops peptide-based therapeutics. The Company's portfolio
includes novel peptide therapeutics for autoimmune diseases and
anti-infectives. The lead program, Lupuzor™, is a first-in class autophagy
immunomodulator for the treatment of Lupus and preclinical analysis suggest
therapeutic activity for many other autoimmune diseases that share the same
autophagy mechanism of action.

 

For additional information about ImmuPharma please visit www.immupharma
(http://www.immupharma) .co.uk

 

ImmuPharma's LEI (Legal Entity Identifier) code : 213800VZKGHXC7VUS895.

 

Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them.

 1    Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Name                                                         Tim McCarthy
 2    Reason for the notification
 a)   Position/status                                              Chairman and Chief Executive Officer
 b)   Initial notification /Amendment                              Initial notification
 3    Details of the issuer, emission allowance market participant, auction
      platform, auctioneer or auction monitor
 a)   Name                                                         ImmuPharma PLC
 b)   LEI                                                          213800VZKGHXC7VUS895
 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted
 a)   Description of the financial instrument, type of instrument  Ordinary Shares of 1p each

      Identification code

                                                                   ISIN: GB0033711010
 b)   Nature of the transaction                                    Grant of share options over new Ordinary Shares
 c)   Price(s) and volume(s)                                       Exercise Price               Volume

      2 pence                                                                                   8,000,000

 d)   Aggregated information                                       N/A

      - Aggregated volume

      - Price

 e)   Date of the transaction                                      18 March 2024
 f)   Place of the transaction                                     n/a

 

 

 1    Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Name                                                         Tim Franklin
 2    Reason for the notification
 a)   Position/status                                              Chief Operating Officer
 b)   Initial notification /Amendment                              Initial notification
 3    Details of the issuer, emission allowance market participant, auction
      platform, auctioneer or auction monitor
 a)   Name                                                         ImmuPharma PLC
 b)   LEI                                                          213800VZKGHXC7VUS895
 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted
 a)   Description of the financial instrument, type of instrument  Ordinary Shares of 1p each

      Identification code

                                                                   ISIN: GB0033711010
 b)   Nature of the transaction                                    Grant of share options over new Ordinary Shares
 c)   Price(s) and volume(s)                                       Exercise Price               Volume

      2 pence                                                                                   6,500,000

 d)   Aggregated information                                       N/A

      - Aggregated volume

      - Price

 e)   Date of the transaction                                      18 March 2024
 f)   Place of the transaction                                     n/a

 

 

 

 1    Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Name                                                         Sebastien Goudreau
 2    Reason for the notification
 a)   Position/status                                              Director
 b)   Initial notification /Amendment                              Initial notification
 3    Details of the issuer, emission allowance market participant, auction
      platform, auctioneer or auction monitor
 a)   Name                                                         ImmuPharma PLC
 b)   LEI                                                          213800VZKGHXC7VUS895
 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted
 a)   Description of the financial instrument, type of instrument  Ordinary Shares of 1p each

      Identification code

                                                                   ISIN: GB0033711010
 b)   Nature of the transaction                                    Grant of share options over new Ordinary Shares
 c)   Price(s) and volume(s)                                       Exercise Price               Volume

      2 pence                                                                                   5,000,000

 d)   Aggregated information                                       N/A

      - Aggregated volume

      - Price

 e)   Date of the transaction                                      18 March 2024
 f)   Place of the transaction                                     n/a

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHBCGDXSBBDGSI